Naslov
Steroid induced hyperglycemia in chemotherapy treated oncology patient

Autori
Miočić, Zara ; Arambašić, Lea ; Galić, Petra ; Bodakoš, Karla ; Petrović, Ana ; Bilić-Ćurčić, Ines

Vrsta, podvrsta i kategorija rada
Sažeci sa skupova, sažetak, stručni

Izvornik
4th International Translational Medicine Congress of Students and Young Physicians OSCON : book of abstracts / Pavlović, Vedrana - Osijek, 2022, 96-96

Skup
4th International Translational Medicine Congress of Students and Young Physicians (OSCON 2022)

Mjesto i datum
Osijek, Hrvatska, 31.03.2022. - 02.04.2022

Vrsta sudjelovanja
Poster

Vrsta recenzije
Nije recenziran

Ključne riječi
chemotherapy ; corticosteroids ; diabetes mellitus ; hyperglycemia

Sažetak
Corticosteroids are widely used drugs, with many known side effects, such as impairment of glycemic control. This adverse effect is seen both in patients with preexisting diabetes and in normoglycemic ones potentially leading to steroid-induced diabetes mellitus. Corticosteroids are largely used in oncology, both as a curative treatment and as a symptom control in supportive care for patients with various malignancies. Case report: We present a 55-year-old woman who was diagnosed with diabetes mellitus type two six years ago. Diabetes was regulated by an endocrinologist who included gliclazide and metformin/sitagliptin in therapy. She was also treated by an oncologist due to a diagnosis of invasive metastasizing breast cancer. As chemotherapy and dexamethasone treatment was introduced by the oncologist, a significant rise in glycemia (15-20 mmol/l) occurred. Following that, she was prescribed postprandial pre-mixed lispro/NPH and gliclazide was discontinued. This approach maintained glycemia in the normal range. However, in days when chemotherapy and dexamethasone was administered, there was an increase in glucose plasma level. Therefore, in addition to current therapy, it was necessary to administer higher doses of insulin on the day of chemotherapy. The last application of dexamethasone was in October 2020. Diabetic therapy remained the same and HbA1c was 7.1%. Conclusion: Hyperglycemia usually occurs in the first 48 hours after administration of high doses of glucocorticoid therapy. Considering that, close monitoring of glucose profiles should be performed. Oncology patients should have their baseline HbA1c and venous plasma glucose when starting steroid therapy.

Izvorni jezik
Engleski

Znanstvena područja
Temeljne medicinske znanosti, Kliničke medicinske znanosti

POVEZANOST RADA